|
시장보고서
상품코드
2016402
인간 융모성 고나도트로핀 시장 보고서 : 기술별, 치료 영역별, 최종사용자별, 지역별(2026-2034년)Human Chorionic Gonadotropin Market Report by Technology, Therapeutic Area, End User, and Region 2026-2034 |
||||||
세계의 인간 융모성 고나도트로핀(HCG) 시장 규모는 2025년에 11억 380만 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 19억 590만 달러에 달하며, 2026-2034년에 CAGR 6.07%로 성장할 것으로 예측하고 있습니다. 여성 불임의 증가, 성선기능저하증 관련 질환의 유병률 증가, 재조합 기술을 이용한 HCG 생산은 시장을 주도하는 주요 요인 중 일부입니다.
인간 융모성 성선자극호르몬(HCG)은 임신 중 태반의 합포체 영양막 세포에서 생성되는 화학물질입니다. 혈액, 소변, 간, 대장, 뇌하수체, 뇌하수체에 존재합니다. HCG는 황체를 자극하여 프로게스테론을 생성하고 임신을 유지하게 합니다. 임상 적용을 위해 이온교환 크로마토그래피, 염료감응 크로마토그래피, 나노 여과, 역상 고속 액체 크로마토그래피(HPLC) 등 다양한 기술을 사용하여 임산부의 소변에서 추출 및 정제됩니다. HCG는 불임 치료, 임신 가능성 향상, 테스토스테론 및 정자 생성 촉진, 남아의 정자 정지 고환 치료 등에 널리 사용되고 있습니다. 또한 임신 관련 질환의 진단 및 경과 관찰, 산전 검사, 부인과 암 진단에도 도움이 됩니다.
인간 융모성 성선자극호르몬(HCG) 시장 동향:
자궁질환, 난관폐쇄, 다낭성난소증후군(PCOS), 내분비계 질환으로 인한 여성 불임 발생률 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. HCG는 배란 유도, 배아 형성 촉진, 난자 채취의 적절한 시기 확보, 자궁 내막 두께 증가 및 자궁 내막의 수용성 향상에 기여하므로 체외수정(IVF), 자궁내 인공수정(IUI) 등 여성 불임 치료의 다양한 생식보조 의료기술에 널리 사용되고 있습니다. 이 외에도 여성의 임신 확률을 높이기 위해 다른 불임 치료제와 함께 본 제품이 널리 사용되고 있는 것도 시장 성장을 촉진하는 또 다른 요인으로 작용하고 있습니다. 또한 비만 및 제2형 당뇨병을 앓고 있는 남성의 성선기능저하증 관련 질환의 유병률이 증가함에 따라 테스토스테론 수치 개선, 생식능력 향상 및 성기능 촉진을 목적으로 하는 HCG의 적용이 증가하고 있으며, 이는 시장 성장을 촉진하고 있습니다. 또한 천연 유래 HCG에 비해 동일한 특성, 강화된 효능, 향상된 안전성, 환자의 내약성을 향상시키는 재조합 기술을 이용한 HCG 생산이 시장 성장에 긍정적인 영향을 미치고 있습니다. 이 외에도 헬스케어 인프라의 급속한 발전, 불임 치료 및 관련 서비스 이용 기회 확대, 고령 인구 증가, 새로운 정제 및 추출 기술 도입을 위한 광범위한 연구개발(R&D) 활동,성 건강 개선을 위한 다양한 정부 정책 시행 등이 시장의 성장을 촉진할 것으로 예상됩니다. 시장의 성장을 촉진할 것으로 예상됩니다.
이 보고서에서 답변하는 주요 질문
- 지금까지 세계 인간 융모성 성선자극호르몬(HCG) 시장의 동향은 어떠했으며, 향후 수년간 어떻게 변화하는가?
- 세계의 인간 융모성 성선자극호르몬(HCG) 시장의 시장 촉진요인, 제약 요인 및 기회는 무엇인가?
- 주요 지역 시장은 어디인가?
- 인간 융모성 성선자극호르몬(HCG) 시장에서 가장 매력적인 국가는 어디인가?
- 기술별로 보면 시장 분석은 어떻게 이루어지는가?
- 치료 영역별 시장 현황은?
- 최종사용자별 시장 분석은 어떻게 이루어지고 있는가?
- 세계의 인간 융모성 성선자극호르몬(HCG) 시장의 경쟁 구조는 어떠한가?
- 세계의 인간 융모성 성선자극호르몬(HCG) 시장의 주요 플레이어/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 인간 융모성 고나도트로핀 시장
제6장 시장 내역 : 기술별
제7장 시장 내역 : 치료 영역별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
제10장 촉진요인·억제요인·기회
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSA 26.05.07The global human chorionic gonadotropin (HCG) market size reached USD 1,103.8 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,905.9 Million by 2034, exhibiting a growth rate (CAGR) of 6.07% during 2026-2034. The rising incidences of infertility in women, increasing prevalence of hypogonadism-related disorders, and production of HCG using recombinant technology represent some of the key factors driving the market.
Human chorionic gonadotropin (HCG) is a chemical produced by syncytiotrophoblastic cells of the placenta during pregnancy. It is found in blood, urine, liver, colon, and pituitary glands. HCG stimulates the corpus luteum to produce progesterone to maintain the pregnancy. It is extracted and purified from the urine of pregnant women for clinical applications using various techniques, such as ion exchange chromatography, dye-affinity chromatography, nanofiltration, and reverse-phase high-performance liquid chromatography (HPLC). HCG is widely used to treat infertility, increase the chances of pregnancy, help in the production of testosterone and sperm, and treat cryptorchidism in male children. It also aids in diagnosing and monitoring pregnancy-related disorders, prenatal screening, and gynecological cancers.
HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET TRENDS:
The rising incidences of infertility among females due to uterine disorders, blocked fallopian tube, polycystic ovarian syndrome (PCOS), and endocrine system disorders are among the key factors driving the market growth. HCG is widely used in various assisted reproductive technologies, such as in-vitro fertilization (IVF) and intrauterine insemination (IUI), to treat female infertility, as it aids in inducing ovulation, promotes the formation of the embryo, facilitates correct timing of oocyte retrieval, increases endometrial thickness, and improve endometrial receptivity. In addition to this, the widespread product utilization in combination with other fertility drugs to increase the chances of pregnancy in women is acting as another growth-inducing factor. Furthermore, the increasing application of HCG to improve testosterone levels, enhance fertility, and promote sexual function due to the increasing prevalence of hypogonadism-related disorders in males suffering from obesity and type 2 diabetes is favoring the market growth. Additionally, the production of HCG using recombinant technology that provides identical properties, enhanced efficacy, and improved safety compared to naturally sourced HCG and enhances patient tolerance is positively influencing the market growth. Other factors, including the rapid development of healthcare infrastructure, increasing availability of treatment and services regarding infertility, rising geriatric population, extensive research and development (R&D) activities for the launch of novel purification and extraction technologies, and the implementation of various government initiatives to improve the sexual health of people, are anticipated to drive the market growth further.
KEY MARKET SEGMENTATION:
Technology Insights:
- Natural Source Extraction
- Recombinant Technology
The report has also provided a detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the technology. This includes natural source extraction and recombinant technology. According to the report, natural source extraction represented the largest segment.
Therapeutic Area Insights:
- Female Infertility Treatment
- Male Hypogonadism
- Oligospermic Treatment
- Others
End User Insights:
- Fertility Clinics
- Research Institutions
- Others
Regional Insights:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for human chorionic gonadotropin (HCG). Some of the factors driving the North America human chorionic gonadotropin (HCG) market include rising incidences of infertility among women, growing consumer awareness regarding the available treatment for infertility and gynecological concerns, and rising expenditure capacities of consumers.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global human chorionic gonadotropin (HCG) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Biocare Medical LLC, Ferring Pharmaceuticals, Fresenius SE & Co. KGaA, Kamiya Biomedical Company (Nitto Boseki Co. Ltd.), Lee Biosolutions Inc. (Oy Medix Biochemica Ab), Merck & Co. Inc., Prospec-Tany Technogene Ltd., Scripps Laboratories Inc., Sun Pharmaceutical Industries Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global human chorionic gonadotropin (HCG) market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global human chorionic gonadotropin (HCG) market?
- What are the key regional markets?
- Which countries represent the most attractive human chorionic gonadotropin (HCG) markets?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the therapeutic area?
- What is the breakup of the market based on the end user?
- What is the competitive structure of the global human chorionic gonadotropin (HCG) market?
- Who are the key players/companies in the global human chorionic gonadotropin (HCG) market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Human Chorionic Gonadotropin (HCG) Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Technology
- 6.1 Natural Source Extraction
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Recombinant Technology
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Therapeutic Area
- 7.1 Female Infertility Treatment
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Male Hypogonadism
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Oligospermic Treatment
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by End User
- 8.1 Fertility Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Research Institutions
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Biocare Medical LLC
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Ferring Pharmaceuticals
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Fresenius SE & Co. KGaA
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Lee Biosolutions Inc. (Oy Medix Biochemica Ab)
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Merck & Co. Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Prospec-Tany Technogene Ltd.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Scripps Laboratories Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Sun Pharmaceutical Industries Limited
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.1 Biocare Medical LLC
